These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 10549714)

  • 21. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
    Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition.
    Momi S; Nasimi M; Colucci M; Nenci GG; Gresele P
    Haematologica; 2001 Mar; 86(3):297-302. PubMed ID: 11255277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deep-vein thrombosis prophylaxis in orthopedic surgery: hip surgery.
    Lassen MR; Backs S; Borris LC; Kaltoft-Sørenson M; Coff-Ganes H; Jeppesen E
    Semin Thromb Hemost; 1999; 25 Suppl 3():79-82. PubMed ID: 10549720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of antithrombotic drugs in older people.
    Tufano A; Cerbone AM; Di Minno G
    Minerva Med; 2002 Feb; 93(1):13-26. PubMed ID: 11850611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Perspectives on antithrombotic agents: from unfractionated heparin to new antithrombotics.
    Agnelli G; Sonaglia F
    Haematologica; 2002 Jul; 87(7):757-70. PubMed ID: 12091128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-molecular-weight heparins for the treatment of acute coronary syndromes.
    Wong GC; Giugliano RP
    Semin Vasc Med; 2003 Nov; 3(4):391-402. PubMed ID: 15199446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors.
    Calatzis A; Peetz D; Haas S; Spannagl M; Rudin K; Wilmer M
    Am J Clin Pathol; 2008 Sep; 130(3):446-54. PubMed ID: 18701419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-molecular-weight heparin in thrombosis and cancer.
    Mousa SA
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():25-30. PubMed ID: 15085463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
    Holzheimer RG
    Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. State of the art--a journey through the world of antithrombotic therapy.
    Turpie AG
    Semin Thromb Hemost; 2002 Aug; 28 Suppl 3():3-11. PubMed ID: 12232817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low molecular weight heparins: the optimal treatment for venous thromboembolism.
    Daskalopoulos ME; Daskalopoulou SS; Liapis CD
    Curr Med Res Opin; 2004 Jul; 20(7):1001-5. PubMed ID: 15265244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation.
    Hoppensteadt D; Walenga JM; Fareed J; Bick RL
    Hematol Oncol Clin North Am; 2003 Feb; 17(1):313-41. PubMed ID: 12627673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bemiparin: second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism.
    Martínez-González J; Vila L; Rodríguez C
    Expert Rev Cardiovasc Ther; 2008 Jul; 6(6):793-802. PubMed ID: 18570617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of venous thromboembolism after ischemic stroke.
    Kase CS; Pineo GF
    Curr Opin Pulm Med; 2008 Sep; 14(5):389-96. PubMed ID: 18664967
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins.
    Jeske WP; Walenga JM; Hoppensteadt DA; Vandenberg C; Brubaker A; Adiguzel C; Bakhos M; Fareed J
    Semin Thromb Hemost; 2008 Feb; 34(1):74-85. PubMed ID: 18393144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heparin and low-molecular-weight heparin.
    Gray E; Mulloy B; Barrowcliffe TW
    Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Low-molecular weight heparins in post-surgical recovery].
    Doutremepuich C; Anne MC; Fernandez G; Pereira F; de Seze O; Doutremepuich F
    Ann Biol Clin (Paris); 1988; 46(3):190-4. PubMed ID: 2841894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low- and ultra-low-molecular-weight heparins.
    Kakkar AK
    Best Pract Res Clin Haematol; 2004 Mar; 17(1):77-87. PubMed ID: 15171959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-molecular-weight heparins in the treatment of cancer-associated thrombosis: a new standard of care?
    Burris HA
    Semin Oncol; 2006 Apr; 33(2 Suppl 4):S3-16; quiz S41-2. PubMed ID: 16638456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile.
    Fareed J; Hoppensteadt D; Schultz C; Ma Q; Kujawski MF; Neville B; Messmore H
    Curr Pharm Des; 2004; 10(9):983-99. PubMed ID: 15078128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.